Results 181 to 190 of about 1,181,836 (211)

A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases

Expert Review of Clinical Immunology, 2015
The development of biologic drugs has undoubtedly enhanced the spectrum of treatments available for immune-mediated inflammatory rheumatic diseases such as rheumatoid arthritis. However, despite their clear clinical benifits, use of biologics is often hindered by their high costs.
openaire   +2 more sources

Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic arthritis: A case report and pharmacokinetic considerations.

International journal of clinical pharmacology and therapeutics
INTRODUCTION The biosimilar CT-P13, the first and only subcutaneous (SC) infliximab formulation, is recommended for patients with psoriatic arthritis (PsA) and can be administered as a maintenance treatment, to be started 4 weeks after the induction ...
M. C. Ditto, S. Parisi, V. Cotugno, D. Barilà, Luca Lo Sardo, F. Cattel, E. Fusaro   +6 more
semanticscholar   +1 more source

Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

International Journal of Colorectal Disease, 2020
In this study, we evaluate the efficacy and safety of the biosimilar infliximab, CT-P13, in the treatment of inpatients with severe steroid-refractory colitis.A retrospective cohort study of adult colitis patients (UC or isolated Crohn's colitis) admitted to the University of Chicago inflammatory bowel disease inpatient service between January 2018 and
Jacob E. Ollech, Inessa Normatov, Noam Peleg, Sushila R. Dalal, Joel Pekow, Dejan Micic, Russel D. Cohen, David T. Rubin, Atsushi Sakuraba   +8 more
openaire   +2 more sources

An Updated Review of Infliximab Biosimilar, CT-P13, in the Treatment of Immune-Mediated Inflammatory Diseases

Immunotherapy, 2020
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed.
Seung Wook Hong, Yong-Gil Kim, Byong Duk Ye   +2 more
openaire   +2 more sources

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

Gastroenterology
CT-P13 subcutaneous (SC) infliximab formulation demonstrated superiority over placebo in maintenance therapy in Crohn's disease (CD) and Ulcerative Colitis (UC) patients in two parallel 54 weeks studies (LIBERTY-CD and LIBERTY-UC).
Stefan Schreiber, J. Colombel, Stephen B. Hanauer, W. Sandborn, B. Sands, S. Danese, Sang Joon Lee, Sung Hyun Kim, Yunju Bae, Sun Hee Lee, S. Lee, J. Lee, Jong Min Kim, S. Yang, Jimin Lee, G. Park, Ju Hyun Lee   +16 more
semanticscholar   +1 more source

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Expert Opinion on Biological Therapy, 2020
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD).
Tommaso Lorenzo Parigi, Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese   +3 more
openaire   +2 more sources

Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study).

Clinics And Research in Hepatology and Gastroenterology
BACKGROUND ReFLECT was a French, prospective, multicenter, observational cohort study evaluating the effectiveness and safety of the infliximab (IFX) biosimilar CT-P13 in a real-world setting.
D. Laharie, Y. Bouhnik, L. Vuitton, A. Biron, G. Pierron, Y. Brault, Maryse Assing, A. Bouzidi, A. Amiot, S. Nancey   +9 more
semanticscholar   +1 more source

CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease

Biologicals, 2016
The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum ...
Kornelius, Schulze, Nadine, Koppka, Frederik, Lutter, Gunnar, Brandhorst, Stefan, Schreiber, Ulf, Helwig   +5 more
openaire   +2 more sources

CT-P13 (an infliximab biosimilar): a guide to its use in the EU

Drugs & Therapy Perspectives, 2015
CT-P13 (Remsima™; Inflectra™) is an infliximab biosimilar approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +1 more source

Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Journal of Gastroenterology and Hepatology, 2019
A biosimilar of infliximab, CT‐P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients.
N. Kim, J. Lee, S. Hong, H. Yoon, H. Kang, S. Lee, J. Im, J. Cha, C. Eun, Ji Won Kim, C. Choi, D. Park   +11 more
semanticscholar   +1 more source